KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Net Income towards Common Stockholders: 2016-2024

Historic Net Income towards Common Stockholders for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to -$116.9 million.

  • Amneal Pharmaceuticals' Net Income towards Common Stockholders rose 54.22% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.6 million, marking a year-over-year increase of 137.94%. This contributed to the annual value of -$116.9 million for FY2024, which is 39.16% down from last year.
  • As of FY2024, Amneal Pharmaceuticals' Net Income towards Common Stockholders stood at -$116.9 million, which was down 39.16% from -$84.0 million recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of $91.1 million in FY2020 and a low of -$130.0 million during FY2022.
  • For the 3-year period, Amneal Pharmaceuticals' Net Income towards Common Stockholders averaged around -$110.3 million, with its median value being -$116.9 million (2024).
  • In the last 5 years, Amneal Pharmaceuticals' Net Income towards Common Stockholders spiked by 125.16% in 2020 and then plummeted by 1,323.51% in 2022.
  • Over the past 5 years, Amneal Pharmaceuticals' Net Income towards Common Stockholders (Yearly) stood at $91.1 million in 2020, then crashed by 88.33% to $10.6 million in 2021, then tumbled by 1,323.51% to -$130.0 million in 2022, then spiked by 35.38% to -$84.0 million in 2023, then plummeted by 39.16% to -$116.9 million in 2024.